|
|
Article: Cepheid Receives FDA Clearance for Xpert[R] HemosIL[R] FII & FV Test.
- Article from:
- Blood Weekly
- Article date:
- October 15, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cepheid (NASDAQ:CPHD) and Instrumentation Laboratory (IL) announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert HemosIL FII & FV test. The test detects Factor II (FII) and Factor V Leiden (FV) genetic variations associated with thrombophilia, an increased risk of blood clots (thrombosis). Xpert HemosIL FII & FV delivers results in just over thirty minutes using a single GeneXpert cartridge. Developed and manufactured by Cepheid, the test will be available worldwide through a partnership with IL, the exclusive worldwide distributor for the Xpert HemosIL FII & FV test (see also Thrombophilia).
"The Xpert ...